161 related articles for article (PubMed ID: 29967572)
1. Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the
Taddio MF; Mu L; Keller C; Schibli R; Krämer SD
Contrast Media Mol Imaging; 2018; 2018():5849047. PubMed ID: 29967572
[TBL] [Abstract][Full Text] [Related]
2. Advancing Estimation of Hepatobiliary Clearances in Physiologically Based Pharmacokinetic Models of Rosuvastatin Using Human Hepatic Concentrations.
Wang L; Zhu Z; Tran D; Seo SK; Pan X
Pharm Res; 2021 Dec; 38(12):2035-2046. PubMed ID: 34862570
[TBL] [Abstract][Full Text] [Related]
3. Evaluating Hepatobiliary Transport with
De Lombaerde S; Kersemans K; Neyt S; Verhoeven J; Vanhove C; De Vos F
Contrast Media Mol Imaging; 2018; 2018():6345412. PubMed ID: 29853807
[TBL] [Abstract][Full Text] [Related]
4. [
Clemente GS; Antunes IF; Sijbesma JWA; van Waarde A; Lammertsma AA; Dömling A; Elsinga PH
Mol Pharm; 2021 Sep; 18(9):3378-3386. PubMed ID: 34351158
[TBL] [Abstract][Full Text] [Related]
5. Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography.
Hernández Lozano I; Karch R; Bauer M; Blaickner M; Matsuda A; Wulkersdorfer B; Hacker M; Zeitlinger M; Langer O
AAPS J; 2019 Apr; 21(4):61. PubMed ID: 31037511
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Transporter-Mediated Drug-Drug Interactions and Phenotyping of Hepatobiliary Transporters Involved in the Clearance of E7766, a Novel Macrocycle-Bridged Dinucleotide.
Jiang R; Hart A; Burgess L; Kim DS; Lai WG; Dixit V
Drug Metab Dispos; 2021 Mar; 49(3):265-275. PubMed ID: 33355210
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
[TBL] [Abstract][Full Text] [Related]
8. Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption.
Huang W; Isoherranen N
CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):571-583. PubMed ID: 32977369
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions.
Taskar KS; Harada I; Alluri RV
Curr Drug Metab; 2021; 22(7):523-531. PubMed ID: 33397250
[TBL] [Abstract][Full Text] [Related]
10. Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model.
Jans HS; Yang XH; Brocks DR; Kumar P; Wuest M; Wiebe LI
J Pharm Pharm Sci; 2018; 21(1s):32s-47s. PubMed ID: 29702045
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of breast cancer resistance protein function in hepatobiliary and renal excretion using PET with 11C-SC-62807.
Takashima T; Wu C; Takashima-Hirano M; Katayama Y; Wada Y; Suzuki M; Kusuhara H; Sugiyama Y; Watanabe Y
J Nucl Med; 2013 Feb; 54(2):267-76. PubMed ID: 23287578
[TBL] [Abstract][Full Text] [Related]
12. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and Radiation Dosimetry of
Garg PK; Lokitz SJ; Nazih R; Garg S
J Nucl Med; 2017 Mar; 58(3):473-478. PubMed ID: 27660145
[TBL] [Abstract][Full Text] [Related]
14. Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A.
Zhou IY; Ramsay IA; Ay I; Pantazopoulos P; Rotile NJ; Wong A; Caravan P; Gale EM
Invest Radiol; 2021 Apr; 56(4):261-270. PubMed ID: 33136686
[TBL] [Abstract][Full Text] [Related]
15. Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs.
Sjögren E; Hedeland M; Bondesson U; Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():214-23. PubMed ID: 24075962
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans.
Kim MS; Song YK; Choi JS; Ji HY; Yang E; Park JS; Kim HS; Kim MJ; Cho IK; Chung SJ; Chae YJ; Lee KR
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986803
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.
Kim SW; Ding YS; Alexoff D; Patel V; Logan J; Lin KS; Shea C; Muench L; Xu Y; Carter P; King P; Constanzo JR; Ciaccio JA; Fowler JS
Nucl Med Biol; 2007 Jul; 34(5):541-51. PubMed ID: 17591554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
